-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Incyte Company reported the Phase I (NCT03762447) clinical data of the oral small molecule PD-L1 inhibitor INCB086550 (NCT03762447) in the Journal for ImmunoTherapy of Cancer
This open-label study included adult patients (≥18 years of age) with advanced solid tumors who developed disease progression after receiving standard therapies or who were intolerant or inapplicable to standard therapies
As of April 9, 2021, a total of 79 patients have received INCB086550 treatment
immunity
The results showed that the ORR of 68 patients with evaluable efficacy was 11.
The following is the specific situation of objective remission of different tumor types
In terms of safety, 46 patients (58.
At the same time, on 2021.
On 2021.
Tumor immunity
According to the previous public information of Betta Pharmaceuticals' application for Hong Kong stocks, BPI-371153 is an innovative, oral small molecule PD-L1 inhibitor that can achieve an anti-tumor immune response comparable to anti-PD-L1 antibodies in preclinical studies
According to the previous public information of Betta Pharmaceuticals' application for Hong Kong stocks, BPI-371153 is an innovative, oral small molecule PD-L1 inhibitor that can achieve an anti-tumor immune response comparable to anti-PD-L1 antibodies in preclinical studies
PD-1/PD-L1 monoclonal antibody has many shortcomings, such as high production cost, lack of oral bioavailability, long tissue retention time and poor membrane permeability, etc.
Small molecule inhibitors can avoid these problems and are of concern to the industry An important direction
.
Leave a message here
